Drugs · acquisition-cost intelligence
Cartia XT
Diltiazem HCL ER· ingredient diltiazemMuscle relaxants· DILTIAZEM HYDROCHLORIDE 120 mg/1; DILTIAZEM HYDROCHLORIDE 180 mg/1; DILTIAZEM HYDROCHLORIDE 240 mg/1; DILTIAZEM HYDROCHLORIDE 300 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.18571
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other diltiazem products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Diltiazem Hydrochloride | $0.06030 | −$0.12540 |
| Cardizem | $0.06893 | −$0.11680 |
| Cardizem CD | $0.18999 | +$0.00430 |
| Diltiazem Hydrochloride Extended-Release | $0.36815 | +$0.18240 |
| Cardizem LA | $1.57 | +$1.39 |
| Diltiazem Hydrochloride Extended-Release | $1.70 | +$1.52 |
| Matzim LA | $1.77 | +$1.59 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 2
Prior auth 0% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.